N-of-One

Sunquest and N-of-One are aiming to help pathologists create actionable, patient-specific genetic reports from NGS panels.

N-of-One will help Agena interpret cancer genomic data generated by its MassArray system as part of a recently launched reporting network.

One deal will see Philips' solution used to improve cancer patient outcomes while the other will beef up its ability to interpret data from oncology tests.

N-of-One will interpret data from HemeSeq profiles for acute myeloid leukemia, chronic lymphocytic leukemia, diffuse large B-cell lymphoma, and other cancers.

N-of-One will provide treatment strategies and clinical trial opportunities for patients based on Inivata's ctDNA liquid biopsy test.

N-of-One will use the funds to develop new oncology clinical decision support solutions, and to expand its sales and marketing efforts.

N-of-One will identify the most relevant therapeutic options for each patient tested with Admera's 64-gene oncology panel.

N-of-One will provide Macrogen with clinical interpretation services for its clinical next-generation sequencing-based cancer panels.

N-of-One will provide clinical and scientific evidence that supports personalized treatment recommendations made on the basis of WuXi Nextcode's tumor-normal sequence interpretation.

N-of-One has launched a new service called PrecisionInsights through which it will provide clinical interpretation for small, targeted gene panels.

Pages

Hundreds of scientists have signed a letter criticizing the open-access Plan S, ScienceInsider reports.

NPR speaks with Rep. Eddie Bernice Johnson (D-Texas) about the US House of Representatives science committee.

A start-up company aiming to match cancer patients to treatments closes after about six weeks, Stat News reports.

In PLOS this week: somatic mutation associations unearthed in thousands of cancer exomes, pathogen detection assay, and more.